

# Hyperglycaemia and the SOAR stroke score in predicting mortality

**Highlight title:** Prognostic value of hyperglycaemia in stroke

Stephen J. McCall<sup>1,2</sup> \*; Turkiah A. Alanazi<sup>1</sup> \*; Allan B. Clark<sup>3</sup>; Stanley D. Musgrave<sup>3</sup>; Joao H. Bettencourt-Silva<sup>3</sup>; Max O. Bachmann<sup>3</sup>; Anthony K. Metcalf<sup>4</sup>; Kristian M. Bowles<sup>3,4</sup>; Mamas A. Mamas<sup>5,6</sup>; John F. Potter DM<sup>3,4</sup>; Phyo K. Myint<sup>1,3</sup>

<sup>1</sup>Ageing Clinical & Experimental Research Group, Institute of Applied Health Sciences, University of Aberdeen, UK

<sup>2</sup>Nuffield Department of Population Health, University of Oxford, Oxford, UK

<sup>3</sup>Norwich Medical School, University of East Anglia, UK

<sup>4</sup>Norfolk and Norwich University Hospital, Norwich, UK

<sup>5</sup>Cardiovascular Research Group, Institutes of Science and Technology in Medicine and Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK

<sup>6</sup>Farr Institute, University of Manchester, Manchester, UK

Stephen J. McCall, Research Associate

Turkiah A. Alanazi, Research Affiliate

Allan B. Clark, Senior Lecturer in Medical Statistics

Stanley D. Musgrave, Senior Research Associate

Joao H. Bettencourt-Silva, Research Associate

Max O. Bachmann, Professor of Health Services Research

Anthony K. Metcalf, Consultant Stroke Physician

Kristian M. Bowles, Professor of Haematology

Mamas A. Mamas, Professor of Cardiology

John F. Potter, Professor of Ageing & Stroke Medicine

Phyo K. Myint, Professor of Medicine of Old Age

**Address for correspondence:** Professor Phyo Kyaw Myint, Room 4:013 Polwarth Building,

School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Foresterhill,

Aberdeen, AB25 2ZD, UK. Tel: +44 (0) 1224 437841, Fax: +44 (0) 1224 437911,

Email: phyo.myint@abdn.ac.uk

\*Joint first authors

**Word count: 2105 (text excl. abstract and tables)**

## **Abstract**

**Background:** We assessed the association between admission blood glucose levels and acute stroke mortality and examined if there was any incremental value of adding glucose status to the validated acute stroke mortality predictor - the SOAR score.

**Methods:** Data from Norfolk and Norwich University Hospital Stroke & TIA register (2003-2013) and Anglia Stroke Clinical Network Evaluation Study (2009-2012) were analysed. Multivariable analysis assessed the association between admission blood glucose levels with inpatient and 7-day mortality. The prognostic ability of the SOAR score was then compared with the SOAR with glucose score(SOAR-G).

**Results:** A total of 5,575 acute stroke patients(ischaemic stroke 89.2%), with mean age(sd) of  $76.97 \pm 11.88$  years were included. Both borderline hyperglycaemia(7.9-11.0mmol/L) and hyperglycaemia(>11.0mmol/L) when compared to normoglycaemia(4.0-7.8mmol/L), were associated with both 7-day and inpatient mortality after controlling for sex, age, OCSF classification and pre-stroke modified Rankin score. Both the SOAR stroke score and SOAR-G were good predictors of inpatient stroke mortality[AUC 0.82(95%CI:0.81-0.84) and 0.83(95%CI:0.81-0.84)], respectively. These scores were also good at predicting outcomes in both patients with and without diabetes.

**Conclusions:** High blood glucose levels at admission were associated with worse acute stroke mortality outcomes. The constituents of the SOAR stroke score were good at predicting mortality after stroke.

## **Key points**

- A borderline hyperglycaemic score and a high SOAR score had an increased likelihood of acute stroke mortality.
- The addition of hyperglycaemia did not improve the prognostic ability of the SOAR score
- The constituents of the SOAR stroke score are good at predicting poor outcomes after stroke without the addition of glucose.

## **Key words**

Hyperglycaemia, Prognostic score, Stroke mortality.

## **Abbreviations:**

aOR: adjusted odds ratio

ASCNES: Anglia Stroke Clinical Network Evaluation Study

AUC: area under the curve

mRS: modified Rankin score

LACS: lacunar stroke;

NNSTR: Norfolk and Norwich University Hospitals Stroke and Transient Ischaemic Attack register

NNUH: Norfolk and Norwich University Hospitals Stroke

PACS: partial anterior circulation stroke

POCS: posterior circulation stroke

OCSP: Oxford Community Stroke Project

SOAR: Stroke subtype, Oxford Community Stroke Project classification, Age, and prestroke modified Rankin score.

SOAR-G: Stroke subtype, Oxford Community Stroke Project classification, Age, prestroke modified Rankin score and glucose.

TACS: total anterior circulation stroke

TIA: Transient Ischaemic Attack

ROC: receiver operating characteristic

uOR: unadjusted odds ratio

## **Introduction**

Hyperglycaemia after acute stroke has a prevalence ranging of 8-20% with many patients having previously diagnosed diabetes mellitus. [1,2] Observational evidence suggests that hyperglycaemia following stroke is strongly associated with poor outcomes and limited neurological recovery. [3]

Scoring systems comprising of simple, easily assessable factors following stroke have been shown to be useful in predicting stroke mortality and length of hospital stay. [4-7] We have previously developed a simple indicator - SOAR Stroke Score, [8] which has been shown to accurately predict acute stroke mortality and length of stay by external validation work. [6,9]

The original SOAR score did not include glucose in its calculation. However, the Get with the Guidelines-Stroke investigators have included a presence of diabetes mellitus in the calculation of their prediction score. [4] Furthermore, the addition of hyperglycaemia to the IScore improved the score's ability to predict 30-day and 1-year mortality after an acute ischaemic stroke. [5]

We are therefore interested in whether including blood glucose status as an additional criterion in the SOAR stroke score would improve the prognostic accuracy. Therefore, the aims of this study were firstly to examine the independent association between blood glucose levels at admission and acute stroke mortality outcomes at 7-days. Secondly, to assess whether adding glucose status to the SOAR score would improve the ability of the SOAR score in predicting 7-day and inpatient mortality. We also considered it important to assess the predictive ability of these scores in patients with and without diabetes mellitus.

## **Material and methods**

The stroke cases included in this study were drawn from two datasets, Norfolk and Norwich University Hospitals (NNUH) Stroke and Transient Ischaemic Attack (TIA) register (NNSTR) and the Anglia Stroke Clinical Network Evaluation Study (ASCNES). Both of these datasets have been previously described. [9-13] Briefly, NNUH Stroke and TIA register was set up in 1996 and has a catchment population of ~750,000. These data were obtained from both paper-based and electronic records, rigorous data entry checks ensured accuracy. [10-12] The study rationale, aims and methods of the ASCNES have been previously reported. [13,14] In brief, this study used routinely collected data from eight specified months between October 2009 and September 2011 and had a one-year follow up of the included patients. The ASCNES collected data from eight acute stroke services from eight NHS Trusts in East of England with a catchment population of ~2.5 million. For calculation of SOAR stroke score, the pre-stroke modified Rankin score (mRS) at admission was extracted from medical records of each patient or was assessed by gaining information from relatives. Admission, discharge dates and mortality status were collected from the acute stroke unit, from which acute hospital stay was obtained.

For both study populations, the patient's medical history, CT or MRI scans were used to ascertain cases of ischaemic and haemorrhagic stroke. TIA, subdural hematoma and subarachnoid haemorrhages were specifically excluded from the study. As ASCNES included NNUH patients (8 study months between 2009 and 2011) to avoid duplication of results any patient who had a duplicate record, one of the records (from NNSTR as a default) was excluded from the current study. For those with recurrent strokes, their first occurrence of stroke was included in the study.

## SOAR score

The SOAR score is an eight point score ranging from score 0-7, which comprises of Stroke subtype (haemorrhagic/ischaemic), Oxford Community Stroke Project classification, Age, and prestroke modified Rankin Score. [8, 9] Glucose levels on admission was added to the SOAR score as a criterion which scores 1 point; the SOAR-G score ranged from 0-8 and gave a person with an abnormal glucose score (either borderline hyperglycaemia or hyperglycaemia) an additional point in the scoring system. The calculation of the new score (SOAR-G) is described in Supplementary Table 1.

## Statistical Analysis

The main exposure of interest was blood glucose levels at admission. The former was categorized into four categories using standard cut off points, hypoglycaemia ( $<4.0$ mmol/L), normoglycemia (4.0-7.8mmol/L), borderline hyperglycaemia (7.9-11.0mmol/L) and hyperglycaemia ( $\geq 11.1$ mmol/L). [15] Only stroke cases with complete data to calculate SOAR and no missing data for admission glucose were included in the current study. The outcomes of interest were 7-day mortality and inpatient mortality. Inpatient mortality included any deaths that occurred during the same admission. 7-day mortality included all deaths within 7 days of hospital admission and status at discharge did not impact inclusion into this outcome.

Data analyses were performed using SPSS V.22.0 (Chicago, Illinois, USA). Unconditional logistic regression models were constructed for both inpatient and 7-day mortality outcomes. This model adjusted for sex, age categories ( $\leq 60$ , 61–79,  $\geq 80$ ), Oxford Community Stroke Project (OCSP) classification (total anterior circulation stroke (TACS), lacunar stroke (LACS), posterior circulation stroke (POCS) and partial anterior circulation stroke (PACS)), pre-stroke mRS (0-5), diabetes status prior to diagnosis and stroke type (ischaemic or

haemorrhagic). Sex was assessed as a confounder in the multivariable regression and there were no data available on ethnicity but majority were white Caucasians (>99.5%). Using the multivariable model, a sensitivity analysis was completed treating admission blood glucose as a continuous variable. Further models were created by stratifying the initial models by stroke type (haemorrhagic and ischaemic stroke types) for both outcomes. Complete case analysis was used to address missing data.

The discriminating ability of SOAR and SOAR-G was compared using receiver operating characteristic (ROC) curves; a combined command was used to assess the equality each of the curves from each score using area under the curve (AUC). A sensitivity analysis was completed; this entailed stratifying each of the ROC curves by diabetes status. These have been presented as area under the curve (AUC) from the ROC curves. STATA V.13SE (STATA Corp, Texas, USA) was used for the ROC curve analysis.

## Results

### I) *Study population characteristics*

The potentially eligible sample consisted of 4,825 patients from the NNSTR and 1,766 patients from the ASCNES; 74 patients had missing discharge status data. A further 116 patients had missing glucose data on admission and 826 patients had other missing clinical or demographic data. As shown in figure 1, this provided a total of 5,575 patients eligible to be included in the study. The sample characteristics are shown in Table 1. The sample mean(sd) age was  $76.96 \pm 11.8$  years, with 48.6% males. Of the whole group 89.2% had an ischaemic stroke and 60.4% had a pre-stroke mRS of 0 (i.e. fully independent). The most common OCSF stroke classification was partial anterior circulation stroke (PACS) with 36.1% of patients. The majority (74.1%) of patients had a normal glucose level on admission with 20.7% of patients known to have diabetes. 18% of the study subjects died as inpatient and 8.4% died within 7-days of admission. The median length of stay was 8 days (IQR 4-18) and the range was 0-180 days.

### II) Glucose level and mortality after stroke

In a multivariate analysis including all stroke types, those with borderline hyperglycaemia, compared to those with normal glucose levels, had an increased likelihood of inpatient mortality with an adjusted odds ratio (aOR) of 1.93 (95%CI: 1.57-2.37) and 7-day mortality with an aOR of 2.18 (95% CI: 1.70-2.80). The likelihood of inpatient and 7-day mortality was not significantly higher for hyperglycaemia versus normoglycaemia (aOR: 2.64 (95%CI: 1.98-3.54) vs. aOR: 3.6 (95%CI: 2.61-5.17), respectively).



### III) Glucose level and mortality after stroke by stroke type

A similar trend was evident for both mortality outcomes when the analysis was stratified by stroke sub-type. The impact on inpatient mortality by having hyperglycaemia compared to a normal glucose level on admission appeared to be greater for haemorrhagic stroke than for ischaemic stroke (aOR 4.92 (95% CI: 2.47-9.77) vs. aOR 2.32 (1.68-3.22)). There was a similar trend for the 7-day mortality outcome. In a sensitivity analysis, the adjusted odds of inpatient mortality increased by 11% per each additional unit increase in glucose level at admission (aOR: 1.11 (95% CI: 1.08 - 1.14)). Similarly, the adjusted odds of 7-day mortality increased by 12% per unit increase in glucose level at admission (aOR: 1.12 (95% CI: 1.09-1.16)).

### IV) SOAR, SOAR-G and mortality outcomes

The overall discriminating value for each SOAR score and mortality outcome is presented in supplementary Table 2. Both the SOAR and SOAR-G scores were highly predictive in discriminating inpatient mortality with an AUC of 0.82 (95% CI: 0.81-0.84) and 0.83 (95% CI: 0.81-0.84), respectively (See Table 3). Similarly, the SOAR and SOAR-G scores were highly predictive in discriminating 7-day mortality with an AUC of 0.80 (95% CI: 0.78-0.82) and 0.82 (95% CI: 0.80-0.84), respectively (See Figures 2a-b). For both outcomes, in the combined analysis, despite a minimal absolute increase in the AUC between the SOAR and SOAR-G scores there was a statistical difference in the predictive ability between the scores, with SOAR-G performing better than SOAR.

### V) Prognostics values stratified by diabetes status

Figures 2c-1f highlights the ROC curve analysis stratified by diabetes status. The SOAR score had very similar predictive abilities when stratified by diabetes diagnosis status, in both

respective outcomes. The SOAR score including glucose had very similar predictive abilities when stratified by diabetes diagnosis status, in both respective outcomes.

## **Discussion**

### *Study summary*

In this study, we confirmed that SOAR stroke score was highly predictive of both inpatient and 7-day mortality. Whilst admission glucose level was an independent predictor of early stroke mortality, addition of glycaemic status to SOAR stroke score did not bring clinically meaningful benefit despite the score's discriminating ability being improved statistically. When this analysis was stratified by diabetes status, both SOAR scores were good at predicting stroke outcomes in both patients with diabetes and patients without diabetes.

### *Findings in context of literature – glucose and stroke outcome*

Our study findings are in consistent with much of the previous literature, as a number of studies have shown a strong association between hyperglycaemia and poor stroke outcome. [16-20] Similar to previous research, this study illustrates that there was a linear association between increased glucose levels and post stroke mortality. [16] Despite this association, there remains debate around the causal relationship between glucose and post stroke outcome. A Cochrane review has shown that there was no evidence to support benefit in maintaining blood glucose at a range of 4-7.5mmol/L after stroke; the main outcomes studied in this system review were death, functionality and neurological deficit. [21]

### *Findings in context of literature – prognostic score*

Despite a statistically significant difference between SOAR and SOAR-G scores, the addition of SOAR with glucose is unlikely to be useful in clinical practice as the improvement in score performance is minimal despite the statistical significance. Stratifying upon diabetes status did not change the predictive ability of the either SOAR score. The most recent Cochrane Review suggested that there is no specific blood glucose threshold that must be

maintained in patients with hyperglycaemia after an acute stroke. [21] This illustrates that the constituents of the SOAR score already contain the informative predictors of poor outcomes after a stroke.

The purposes of this study were to assess whether in our population, glucose level after stroke was associated with poor outcomes and if so whether the addition of glycaemic status to the SOAR stroke score improved its prognostic ability. As this association existed we further assessed whether it would improve the predictive ability of an established SOAR stroke score. The data from our study suggests that although an increase in glucose level was associated with mortality it did not materially change the predictive ability of the SOAR score.

#### *Strengths and weaknesses*

Our prospectively collected study had a relatively large and representative sample using the data from multiple centres across the East Anglia. The SOAR score itself is very easy to obtain and calculate, unlike other prognostic measures, this makes it a very practical measure to use in a clinical setting. [6,8] As this was an observational study, it cannot imply the causal relationship between glucose and stroke outcome. The use of data from hospital-based registries may be a potential limitation of this study as severe strokes that resulted in death in the community were not included in the registry, similarly mild strokes may have not attended secondary care. [8] However, the truncation of distribution will only attenuate the observed associations. Further prognostic information of mortality is irrelevant to those who died prior to admission and those who sustained mildest forms of stroke with almost 0% chance of mortality from the event. [8,22]

### *Conclusion*

To conclude, we have shown that both SOAR stroke score and SOAR with glucose score were very good at predicting both inpatient and 7-day mortality after an acute stroke.

Although there was a statistically significant difference between the scores, the added value of including glucose to the SOAR did not clinically increase its discriminating ability in an unselected stroke patient population.

## **Table & Figure Legends**

**Table 1:** The overall sample characteristics of the combined ASCNES and NNUH datasets

**Table 2:** Multivariate analysis examining the risk of mortality for glucose levels and patient characteristics by all stroke types, ischaemic and haemorrhagic strokes.

**Table 3:** The predictive ability of the SOAR scores for mortality outcomes: using receiving operating characteristic curves.

**Figure 1.** Derivation of study population

**Figure 2a.** Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR and SOAR with glucose score

**Figure 2b.** Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR and SOAR with glucose score

**Figure 2c.** Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR and stratified by diabetes status before diagnosis

**Figure 2d.** Receiver Operating Characteristic curve differentiating inpatient mortality using SOAR with glucose score stratified by diabetes status before diagnosis

**Figure 2e.** Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR and stratified by diabetes status before diagnosis

**Figure 2f.** Receiver Operating Characteristic curve differentiating 7-day mortality using SOAR with glucose score stratified by diabetes status before diagnosis

**Supplementary Table 1.** Scoring system for SOAR-G index

**Supplementary Table 2.** The predictive ability of the SOAR stroke score and SOAR stroke score with glucose for both inpatient and 7 day mortality.

## **Contributions**

PKM is the PI of both NNUSTR and ASCNES. PKM conceived the idea. SDM and JBHS performed data linkages. SJM and TAA did literature search, cleaned and analysed the data under supervision of ABC. JFP, MOB and AKM are co-I of ASCNES and JFP, KMB and AKM are co-I of NNUSTR. SJM and PKM drafted the manuscript. All authors contributed in writing the paper. PKM is the guarantor.

## **Acknowledgement**

We gratefully acknowledge the data teams of the eight NHS Trusts which made up the ASCNES and the data team at the Norfolk and Norwich NHS Foundation Trust.

## **Funding**

We would like to acknowledge the funders of the Anglia Stroke Clinical Network Evaluation Study (ASCNES) and the Norfolk and Norwich Stroke and TIA Register. ASCNES is funded by the National Institute for Health Research (NIHR) Research for Patient Benefit Programme (PB-PG-1208-18240). This work presents independent research funded by the NIHR under its Research for Patient Benefit (RfPB) programme (Grant Reference Number PB-PG-1208-18240). The views expressed are those of the author (s) and not necessarily those of the NHS, the NIHR or the Department of Health. The NNUH Stroke and TIA Register is maintained by the NNUH NHS Foundation Trust Stroke Services and data management for this study is supported by the NNUH Research and Development Department through Research Capability Funds.

## **Ethical approval**

Both NNUH Stroke & TIA register and ASCNES received the ethical approval.

**Disclosures:** None

## References

- 1 Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). *The Lancet Neurology* 2007;**6**:397-406.
- 2 Toni D, Sacchetti ML, Argentino C, et al. Does hyperglycaemia play a role on the outcome of acute ischaemic stroke patients? *J Neurol* 1992;**239**:382-386.
- 3 Guyomard V, Jamieson E, Myint PK. Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting. *Current topics in medicinal chemistry* 2009;**9**:1261-1277.
- 4 Smith EE, Shobha N, Dai D, et al. Risk score for in-hospital ischemic stroke mortality derived and validated within the get with the guidelines-stroke program. *Circulation* 2010;**122**:1496-1504.
- 5 Saposnik G, Kapral MK, Liu Y, et al. IScore: A risk score to predict death early after hospitalization for an acute ischemic stroke. *Circulation* 2011;**123**:739-749.
- 6 Kwok CS, Potter JF, Dalton G, et al. The SOAR stroke score predicts inpatient and 7-day mortality in acute stroke. *Stroke* 2013;**44**:2010-2012.
- 7 Cheung RTF, Zou L-. Use of the original, modified, or new intracerebral hemorrhage score to predict mortality and morbidity after intracerebral hemorrhage. *Stroke* 2003;**34**:1717-1722.
- 8 Myint PK, Clark AB, Kwok CS, et al. The SOAR (Stroke subtype, Oxford Community Stroke Project classification, Age, prestroke modified Rankin) score strongly predicts early outcomes in acute stroke. *International Journal of Stroke* 2014;**9**:278-283.



9 Kwok, CS. Clark, AB. Musgrave, SD. Potter, JF. Dalton, G. Day, DJ. George, A. Metcalf, AK. Ngeh, J. Nicolson, A. Owusu-Agyei, P. Shekhar, R. Walsh, K. Warburton, EA.

Bachmann, MO. Myint PK. The SOAR stroke score predicts hospital length of stay in acute stroke: an external validation study. *International Journal of Clinical Practice* 2015;**69**:659-665.

10 White JR, Bettencourt-Silva JH, Potter JF, et al. Changes in antiplatelet use prior to incident ischaemic stroke over 7 years in a UK centre and the association with stroke subtype. *Age Ageing* 2013;**42**:594-598.

11 Kwok CS, Skinner J, Metcalf AK, et al. Prior antiplatelet or anticoagulant therapy and mortality in stroke. *Heart* 2012;**98**:712-717.

12 Guyomard V, Fulcher RA, Redmayne O, et al. Effect of dysphasia and dysphagia on inpatient mortality and hospital length of stay: A database study. *J Am Geriatr Soc* 2009;**57**:2101-2106.

13 Kwok CS, Musgrave SD, Price GM, et al. Similarity of patient characteristics and outcomes in consecutive data collection on stroke admissions over one month compared to longer periods. *Acta Vet Scand* 2014;**342**.

14 Myint PK, Potter JF, Price GM, et al. Evaluation of stroke services in Anglia stroke clinical network to examine the variation in acute services and stroke outcomes. *BMC Health Services Research* 2011;**11**:50.

15 World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO. 2006;.

16 Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. *Neurology* 2002;**59**:669-674.

17 Weir CJ, Murray GD, Dyker AG, et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. *Br Med J* 1997;**314**:1303-1306.

18 McCall AL. The impact of diabetes on the CNS. *Diabetes* 1992;**41**:557-570.

19 Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. *Ann Neurol* 2002;**52**:20-28.

20 Furie K, Inzucchi SE. Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. *Current Neurology and Neuroscience Reports* 2008;**8**:12-19.

21 Bellolio MF, Gilmore RM, Ganti L. Insulin for glycaemic control in acute ischaemic stroke. *The Cochrane Library* 2014;.

22 Espallargues M, Philp I, Seymour DG, et al. Measuring case-mix and outcome for older people in acute hospital care across Europe: the development and potential of the ACMEplus instrument. *QJM* 2008;**101**:99-109.

Supplementary Table 1. Scoring system for SOAR-G index

Patient Variables		Score	Variable	Score	
Age categories	≤60	0	Pre-stroke mRS	0	0
	61–65	0		1	0
	66–70	1		2	0
	71–75	1		3	1
	76–80	1		4	1
	81–85	1		5	2
	86–90	2			
	91+	2			
OCSP classification	TACS	2	Glucose level	Normal	0
	PACS	0		Hypoglycaemia	0
	LACS	0		Borderline hyperglycaemia	1
	POCS	1		Hyperglycaemia	1
Stroke type	Infarct	0	Gender	Male	0
	Haemorrhage	1		Female	0

Supplementary Table 2 The predictive ability of the SOAR stroke score and SOAR stroke score with glucose for both in-patient and 7 day mortality.

In-patient mortality																	
SOAR Score	Sensitivity		95% CI		Specificity		95% CI			Positive predictive value		95% CI		Negative predictive value		95% CI	
0	99.5	98.84	99.84	9.9	9.05	10.8	19.43	18.35	20.54	98.91	97.47	99.64					
≥1	89.79	87.74	91.6	51.2	49.74	52.66	28.66	27.08	30.28	95.83	94.96	96.59					
≥2	76.18	73.41	78.79	77.78	76.54	78.97	42.8	40.49	45.14	93.73	92.91	94.48					
≥3	45.85	42.72	48.99	93.27	92.5	93.98	59.79	56.22	63.29	88.75	87.82	89.63					
≥4	15.82	13.61	18.23	98.3	97.88	98.65	66.95	60.55	72.92	84.25	83.24	85.22					
≥5	3.3	2.28	4.61	99.65	99.43	99.8	67.35	52.46	80.05	82.52	81.49	83.51					
≥6	-	-	-	-	-	-	-	-	-	-	-	-					
7_Day mortality																	
0	99.15	97.84	99.77	8.89	8.13	9.71	9.11	8.33	9.93	99.13	97.78	99.76					
≥1	91.49	88.59	93.85	47.11	45.73	48.49	13.74	12.55	14.99	98.36	97.78	98.83					
≥2	77.87	73.84	81.55	72.34	71.09	73.56	20.58	18.73	22.54	97.26	96.69	97.76					
≥3	48.72	44.12	53.34	89.48	88.61	90.31	29.9	26.67	33.28	94.99	94.33	95.59					
≥4	17.87	14.51	21.64	97.02	96.52	97.47	35.59	29.49	42.06	92.77	92.04	93.45					
≥5	3.62	2.12	5.73	99.37	99.12	99.57	34.69	21.67	49.64	91.8	91.05	92.51					
≥6	-	-	-	-	-	-	-	-	-	-	-	-					
Inpatient mortality																	
SOAR + Glucose Score	Sensitivity		95% CI		Specificity		95%CI			Positive predictive value		95%CI		Negative predictive value		95% CI	
0	99.6	98.98	99.89	7.89	7.12	8.71	19.1	18.04	20.19	98.9	97.22	99.7					
≥1	92.59	90.79	94.14	42.77	41.33	44.22	26.1	24.66	27.58	96.36	95.45	97.13					
≥2	81.28	78.72	83.66	71.74	70.41	73.05	38.57	36.49	40.69	94.61	93.81	95.34					
≥3	57.86	54.73	60.94	89.84	88.93	90.7	55.42	52.34	58.46	90.71	89.83	91.54					
≥4	28.83	26.04	31.75	96.96	96.42	97.44	67.45	62.78	71.87	86.19	85.22	87.12					
≥5	8.61	6.94	10.52	99.21	98.91	99.45	70.49	61.56	78.4	83.26	82.24	84.24					
≥6	1.4	0.77	2.34	99.93	99.81	99.99	82.35	56.57	96.2	82.28	81.25	83.27					
≥7	-	-	-	-	-	-	-	-	-	-	-	-					
7-Day mortality																	
0	99.36	98.15	99.87	7.09	6.4	7.83	8.96	8.2	9.77	99.18	97.62	99.83					
≥1	93.83	91.26	95.83	39.22	37.87	40.57	12.44	11.37	13.58	98.57	97.96	99.04					
≥2	84.04	80.41	87.24	66.5	65.19	67.8	18.76	17.12	20.5	97.84	97.3	98.3					
≥3	62.34	57.79	66.74	85.31	84.31	86.27	28.09	25.38	30.93	96.09	95.49	96.64					
≥4	34.04	29.76	38.52	94.77	94.12	95.36	37.47	32.86	42.25	93.98	93.29	94.61					
≥5	10.43	7.81	13.55	98.57	98.21	98.88	40.16	31.39	49.42	92.28	91.54	92.97					
≥6	1.91	0.88	3.6	99.84	99.69	99.93	52.94	27.81	77.02	91.71	90.95	92.42					
≥7	-	-	-	-	-	-	-	-	-	-	-	-					

Figure 1. Derivation of study population




Figure 2a. Receiver Operating Characteristic curve differentiating **inpatient mortality** using SOAR and SOAR with glucose score




Figure 2b. Receiver Operating Characteristic curve differentiating **7-day mortality** using SOAR and SOAR with glucose score




Figure 2c. Receiver Operating Characteristic curve differentiating **inpatient mortality** using SOAR and stratified by diabetes status before diagnosis




Figure 2d. Receiver Operating Characteristic curve differentiating **inpatient mortality** using SOAR with glucose score stratified by diabetes status before diagnosis




Figure 2e. Receiver Operating Characteristic curve differentiating **7-day mortality** using SOAR and stratified by diabetes status before diagnosis




Figure 2f. Receiver Operating Characteristic curve differentiating **7-day mortality** using SOAR with glucose score stratified by diabetes status before diagnosis






Table 1. The overall sample characteristics of the combined ASCNES and NNUH datasets.

		<b>Total sample n (%)</b>	<b>Death n (%)</b>	<b>7 Day mortality n (%)</b>
			<b>n=999</b>	<b>n=470</b>
<b>Age category</b>	<b>≤60 years</b>	538 (9.7)	27 (2.7)	24 (5.1)
	<b>61–79 years</b>	2303 (41.3)	263 (26.3)	140 (29.8)
	<b>&gt;79 years</b>	2734 (49)	709 (71.0)	306 (65.1)
<b>Sex</b>	<b>Male</b>	2707 (48.6)	407 (59.3)	270 (57.4)
	<b>Female</b>	2868 (51.4)	592 (40.7)	200 (42.6)
<b>Stroke type</b>	<b>Ischaemic</b>	4974 (89.2)	790 (79.1)	331 (70.4)
	<b>Haemorrhage</b>	601 (10.8)	209 (20.9)	139 (29.6)
<b>OCSP classification</b>	<b>TACS</b>	1202 (21.6)	619 (62.0)	317 (67.4)
	<b>PACS</b>	2015 (36.1)	196 (19.6)	56 (11.9)
	<b>LACS</b>	1405 (25.2)	50 (5.0)	18 (3.8)
	<b>POCS</b>	953 (17.1)	134 (13.4)	79 (16.8)
<b>Pre-stroke mRS</b>	<b>0</b>	3366 (60.4)	447 (44.7)	240 (51.1)
	<b>1</b>	747 (13.4)	140 (14.0)	62 (13.2)
	<b>2</b>	529 (9.5)	111 (11.1)	52 (11.1)
	<b>3</b>	527 (9.5)	140 (14.0)	50 (10.6)
	<b>4</b>	282 (5.1)	109 (10.9)	46 (9.8)
	<b>5</b>	124 (2.2)	52 (5.2)	20 (4.3)
<b>Random plasma glucose level</b>	<b>Hypoglycaemia (&lt;4.0mmol/L)</b>	51 (0.9)	7 (0.7)	3 (0.6)
	<b>Normal (4.0-7.8mmol/L),</b>	4132 (74.1)	595 (59.6)	245 (52.1)
	<b>Borderline hyperglycaemia (7.9-11.0mmol/L)</b>	918 (16.5)	264 (26.4)	142 (30.2)
	<b>Hyperglycaemia (≥11.1mmol/L)</b>	474 (8.5)	133 (13.3)	80 (17.0)
<b>Diabetes before diagnosis</b>	<b>No</b>	4420 (79.3)	790 (79.1)	382 (81.3)
	<b>Yes</b>	1155 (20.7)	209 (20.9)	88 (18.7)

TACS, total anterior circulation stroke; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; LACS, lacunar stroke; mRS, modified Rankin score; OCSP, Oxford Community Stroke Project.

Table 2. Multivariate analysis examining the risk of mortality for glucose levels and patient characteristics by all stroke types, ischemic and haemorrhagic strokes.

Both stroke types	OR	Inpatient death			Early death Within 7 days		
			95% CI	P	OR	(95% CI)	P
Glucose level	Normal	1			1		
	Hypoglycaemia	0.99	[0.39-2.53]	0.99	1.29	[0.36-4.60]	0.69
	Borderline hyperglycaemia	1.93	[1.57-2.37]	<0.001	2.18	[1.70-2.80]	<0.001
	Hyperglycaemia	2.64	[1.98-3.54]	<0.001	3.67	[2.61-5.17]	<0.001
<b>Haemorrhagic stroke</b>							
Glucose level	Normal	1			1		
	Hypoglycaemia	3.32	[0.08-143.26]	0.53	-	-	-
	Borderline hyperglycaemia	2.9	[1.75-4.79]	<0.001	3.09	[1.86-5.13]	<0.001
	Hyperglycaemia	4.92	[2.47-9.77]	<0.001	5.6	[2.80-11.20]	<0.001
<b>Ischemic stroke</b>							
Glucose level	Normal	1			1		
	Hypoglycaemia	0.9	[0.34-2.40]	0.83	1.56	[0.44-5.49]	0.49
	Borderline hyperglycaemia	1.76	[1.40-2.21]	<0.001	1.95	[1.45-2.61]	<0.001
	Hyperglycaemia	2.32	[1.68-3.22]	<0.001	3.33	[2.23-4.96]	<0.001

Adjusted for sex, age, pre-stroke mRS, OSCP classification, diabetes before diagnosis, stroke type(excluding stratified models).

Table 3. The predictive ability of the SOAR scores for mortality outcomes: using receiving operating characteristic curves.

Outcome	Prognostic score	Area under the curve	95% Confidence Interval	P-value
Inpatient mortality	SOAR	0.82	(0.807-0.836)	0.027
	SOAR with glucose	0.83	(0.813-0.841)	
7-day mortality	SOAR	0.80	(0.783-0.822)	<0.001
	SOAR with glucose	0.82	(0.797-0.836)	